No Data
No Data
Looking Into Ascendis Pharma's Recent Short Interest
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $191
No Data
No Data